Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an investor for the immediate cash exercise of July 2026 warrants to purchase 857,462 shares at $5.75 per share. The resale of these shares is covered by an effective Form S-3 registration statement.
Autonomix expects approximately $4.9 million in gross proceeds before fees. In return, the investor will receive unregistered Series E-1 and Series E-2 warrants, each for 535,913 shares, exercisable immediately at $6.25 per share and expiring five years after issuance. Closing is expected on or about August 26, 2026, subject to customary conditions.
Positive
- $4.9 million expected gross cash proceeds from warrant exercise
- Immediate exercise of 857,462 existing warrants provides near-term funding certainty
- New warrants cover up to 1,071,826 additional shares at $6.25 per share
- New warrant exercise prices set at a premium to prior $5.75 warrant exercise price
Negative
- Exercise of 857,462 warrants increases outstanding common shares and dilutes existing holders
- New Series E-1 and E-2 warrants for 1,071,826 shares create additional potential future dilution
- New warrants and underlying shares are initially unregistered, limiting immediate resale flexibility for the investor
News Explained
The planned cash inflow is conditional, while the new warrants preserve a future path to additional shares and dilution.
The agreement has been entered but is not yet closed; if completed, Autonomix Medical would receive approximately
The new warrants are being issued in a private placement, so they are unregistered and may be resold only after SEC registration or under an applicable exemption; the company has agreed to file a registration statement for those resales.
The expected gross proceeds equal
The next defined milestone is the expected
Sources and calculations
- Autonomix Medical warrant inducement release (2026-08-24)
- Dilution definition (2026-07-17)
- Private placement / PIPE definition (2026-07-17)
- Latest-quarter fundamentals (2027Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $4,900,000 / ($3,544,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $3,460,000 / ($3,544,000 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Preclinical study completion | Positive | -17.4% | Completed GLP preclinical study supporting planned FDA submission |
| Aug 10 | Leadership award | Positive | -7.5% | Chief medical officer received a cardiovascular technology lifetime achievement award |
| Aug 04 | Patent issuance | Positive | +434.3% | New patent expanded protection for precision neuromodulation technologies |
| Jul 24 | Preclinical study results | Positive | -16.6% | Renal nerve sensing study demonstrated neural activity changes after ablation |
| Jul 23 | Patent issuance | Positive | -12.1% | New patent broadened autonomic nervous system assessment technology protection |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AMIX diverged from positive news in four of five recent events, with one aligned positive reaction.
Key Terms
warrant inducement agreement financial
form s-3 regulatory
private placement financial
1933 act regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of
Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction.
In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series E-1 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock, and unregistered Series E-2 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock (collectively, the “New Warrants”). The New Warrants will each have an exercise price of
The closing of the warrant exercise transaction is expected to occur on or about August 26, 2026, subject to satisfaction of customary closing conditions.
The New Warrants described above are being offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements include, without limitation, the satisfaction of customary closing conditions related to the warrant transaction and the completion of the warrant transaction. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, including, but not limited to, the expected completion, timing and size of the warrant transaction, the intended use of proceeds from the transaction and Autonomix’s ability to file a registration statement registering the resale of the securities sold in the transaction. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
